drugset / Trial / NCT07546214

A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.

NCT07546214

Phase 1 Completed 575 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

To demonstrate therapeutic equivalence and safety of Tapinarof Cream, 1% (Sun pharma Canada, Inc.) and Vtama® (Tapinarof) Cream, 1% in the treatment of plaque psoriasis.

Timeline

Start
2025-10-13
Primary completion
2026-03-18
Completion
2026-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Tapinarof Other / unclassified 1 % Topical

Indications